| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 25mg | |||
| Other Sizes |
| Targets |
Maralixibat targets ASBT (SLC10A2), the ileal bile acid transporter. By inhibiting this transporter, it blocks the reabsorption of bile acids in the terminal ileum, reducing enterohepatic recirculation and increasing fecal excretion of bile acids.
|
|---|---|
| ln Vitro |
In vitro, maralixibat chloride inhibits ASBT-mediated bile acid transport. It reduces elevations in serum bile acid (sBA) levels and improves liver function in preclinical models.
|
| ln Vivo |
Maralixibat chloride enhanced liver function, decreased liver tissue damage, and decreased high sBA levels in a rat partial bile duct ligation model of cholestasis [2].
In vivo, maralixibat chloride reduces elevations in sBA levels, improves liver function, and reduces liver tissue damage in a rat partial bile duct ligation model of cholestasis. It works by reducing systemic levels of bile acids. |
| Enzyme Assay |
In vitro transporter assays typically measure the inhibition of bile acid uptake by cells expressing ASBT. Maralixibat is incubated with cells and radiolabeled bile acids, and the IC50 for inhibition of uptake is determined.
|
| Cell Assay |
In vitro cellular assays evaluate the inhibition of bile acid transport using cell lines overexpressing ASBT. Cells are treated with maralixibat, and the uptake of radiolabeled bile acids is measured. The IC50 for inhibition is calculated from dose-response curves.
|
| Animal Protocol |
In vivo animal experiments are conducted in rat models of cholestasis, such as the partial bile duct ligation model. Maralixibat is administered orally, and efficacy is assessed by measuring serum bile acid levels, liver function tests, and liver histology.
|
| ADME/Pharmacokinetics |
Maralixibat chloride has a molecular formula of C40H56ClN3O4S and a molecular weight of 710.42. It has a CAS number of 228113-66-4. The compound is orally active and soluble in DMSO at 10 mM.
|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation There is currently no information regarding the use of malariziba during lactation. Because malariziba is poorly absorbed orally and 90% is bound to plasma proteins, the concentration in breast milk may be very low. If a mother needs to take malariziba, she should not discontinue breastfeeding. ◉ Effects on Breastfed Infants No published information found as of the revision date. ◉ Effects on Lactation and Breast Milk No published information found as of the revision date. The toxicity profile of maralixibat is related to its mechanism as an IBAT inhibitor. By reducing bile acid reabsorption, it can affect lipid and fat-soluble vitamin absorption. The compound has been evaluated in preclinical and clinical studies for safety in cholestatic liver diseases. |
| References | |
| Additional Infomation |
See also: Maralixibat (containing the active ingredient).
Drug Indications Rivamali is indicated for the treatment of cholestatic pruritus in patients with Alajile syndrome (ALGS) for 2 months or longer. Treatment of progressive familial intrahepatic cholestasis Treatment of Alajile syndrome Treatment of biliary atresia Maralixibat chloride is being developed for the treatment of rare cholestatic liver diseases, including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia. It is also known as LUM-001 and SHP625. |
| Molecular Formula |
C40H56CLN3O4S
|
|---|---|
| Molecular Weight |
710.42
|
| Exact Mass |
709.367
|
| CAS # |
228113-66-4
|
| Related CAS # |
228113-66-4 (chloride);716313-53-0 (cation);Maralixibat bromide; Maralixibat chloride hydrate;
|
| PubChem CID |
9831642
|
| Appearance |
White to light yellow solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
49
|
| Complexity |
1080
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCCCC1(CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)[C@H]([C@H]1O)C3=CC=C(C=C3)OCC4=CC=C(C=C4)C[N+]56CCN(CC5)CC6)CCCC.[Cl-]
|
| InChi Key |
LOKHDANEXNQHHE-QWXPGWJZSA-M
|
| InChi Code |
InChI=1S/C40H56N3O4S.ClH.H2O/c1-5-7-19-40(20-8-6-2)30-48(45,46)37-18-15-34(41(3)4)27-36(37)38(39(40)44)33-13-16-35(17-14-33)47-29-32-11-9-31(10-12-32)28-43-24-21-42(22-25-43)23-26-43/h9-18,27,38-39,44H,5-8,19-26,28-30H2,1-4H31H1H2/q+1/p-1/t38-,39-/m1../s1
|
| Chemical Name |
1-(4-((4-((4R,5R)-3,3-dibutyl-7-(dimethylamino)-4-hydroxy-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b]thiepin-5-yl)phenoxy)methyl)benzyl)-1,4-diazabicyclo[2.2.2]octan-1-ium chloride hydrate
|
| Synonyms |
LUM-001 SHP-625LUM001 SHP 625LUM 001 SHP625 LivmarliLopixibat chloride Maralixibat Maralixibat chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~70.38 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4076 mL | 7.0381 mL | 14.0762 mL | |
| 5 mM | 0.2815 mL | 1.4076 mL | 2.8152 mL | |
| 10 mM | 0.1408 mL | 0.7038 mL | 1.4076 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
